These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28343544)

  • 1. Sequential Immunologic Reactions after Suspension of Nivolumab Treatment in Lung Adenocarcinoma Patient.
    Shirasu H; Ono A; Takahashi T
    J Thorac Oncol; 2017 Apr; 12(4):e33-e34. PubMed ID: 28343544
    [No Abstract]   [Full Text] [Related]  

  • 2. Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1.
    Iwata T; Yamamoto A; Hara K
    J Thorac Oncol; 2017 Dec; 12(12):e205-e207. PubMed ID: 29169526
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe Pneumonitis after Nivolumab Treatment Accompanied by Acute Pulmonary Embolism in a Patient with Lung Adenocarcinoma.
    Liao JP; Nie LG; Que CL; Mu XD
    Chin Med J (Engl); 2017 Nov; 130(22):2755-2756. PubMed ID: 29133768
    [No Abstract]   [Full Text] [Related]  

  • 4. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
    Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
    World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic Adaptation of Tumor Immune Response With Nivolumab Demonstrated by 18F-FDG PET/CT.
    Eshghi N; Lundeen TF; Kuo PH
    Clin Nucl Med; 2018 Feb; 43(2):114-116. PubMed ID: 29261621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudoprogression in lung adenocarcinoma during treatment with nivolumab.
    Izumida T; Kawagishi Y; Tsuji H
    BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28500114
    [No Abstract]   [Full Text] [Related]  

  • 7. Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment.
    Kumagai T; Kimura M; Inoue T; Tamiya M; Nishino K; Imamura F
    Thorac Cancer; 2017 May; 8(3):275-277. PubMed ID: 28371397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer.
    Catania C; Passaro A; Rocco EG; Spitaleri G; Barberis M; Noberasco C; Signore ED; Travaini L; de Marinis F
    Clin Lung Cancer; 2016 Sep; 17(5):e179-e183. PubMed ID: 27349506
    [No Abstract]   [Full Text] [Related]  

  • 9. Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report.
    Pluchart H; Pinsolle J; Cohen J; Ferretti GR; Bedouch P; Giaj Levra M; Toffart AC; Moro-Sibilot D
    J Med Case Rep; 2017 Jul; 11(1):183. PubMed ID: 28679408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Significant Antitumor Activity of Nivolumab in Lung Adenocarcinoma with Choriocarcinomatous Features.
    Ochi M; Miyamoto S; Terada Y; Furuhata Y; Awano N; Izumo T; Ikushima S; Bae Y; Kumasaka T; Kunito H
    Intern Med; 2018 Jun; 57(12):1773-1777. PubMed ID: 29434118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression.
    Tanizaki J; Hayashi H; Kimura M; Tanaka K; Takeda M; Shimizu S; Ito A; Nakagawa K
    Lung Cancer; 2016 Dec; 102():44-48. PubMed ID: 27987588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced Lung Adenocarcinoma with Nivolumab-associated Dermatomyositis.
    Kudo F; Watanabe Y; Iwai Y; Miwa C; Nagai Y; Ota H; Yabe H; Demitsu T; Hagiwara K; Koyama N; Koyama S
    Intern Med; 2018 Aug; 57(15):2217-2221. PubMed ID: 29526968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma.
    Shirasu H; Ono A; Omae K; Nakashima K; Omori S; Wakuda K; Kenmotsu H; Naito T; Murakami H; Endo M; Nakajima T; Takahashi T
    Tumour Biol; 2018 Feb; 40(2):1010428318760420. PubMed ID: 29463190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.
    Haratake N; Toyokawa G; Tagawa T; Kozuma Y; Matsubara T; Takamori S; Akamine T; Yamada Y; Oda Y; Maehara Y
    Anticancer Res; 2017 Oct; 37(10):5713-5717. PubMed ID: 28982891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer.
    Takaya K; Sonoda M; Fuchigami A; Hiyoshi T
    Intern Med; 2017 Sep; 56(18):2463-2469. PubMed ID: 28824067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial Remission of Hepatic Metastatic Lesion but Complicated with Secondary and Refractory Fever Lead by Nivolumab in a Patient with Lung Adenocarcinoma Presenting Gefitinib Acquired Resistance.
    Lian ZZ; Sun YF; Chen C
    Chin Med J (Engl); 2016 Apr; 129(7):879-80. PubMed ID: 26996489
    [No Abstract]   [Full Text] [Related]  

  • 17. Immune-related bone marrow failure following anti-PD1 therapy.
    Michot JM; Vargaftig J; Leduc C; Quere G; Burroni B; Lazarovici J; Champiat S; Ribrag V; Lambotte O
    Eur J Cancer; 2017 Jul; 80():1-4. PubMed ID: 28527392
    [No Abstract]   [Full Text] [Related]  

  • 18. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report.
    Ikeuchi K; Okuma Y; Tabata T
    Lung Cancer; 2016 Sep; 99():148-50. PubMed ID: 27565931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report.
    Uenami T; Hosono Y; Ishijima M; Kanazu M; Akazawa Y; Yano Y; Mori M; Yamaguchi T; Yokota S
    Lung Cancer; 2017 Jul; 109():42-44. PubMed ID: 28577948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab-Induced Severe Akathisia in an Advanced Lung Cancer Patient.
    Abe J; Sato T; Tanaka R; Okazaki T; Takahashi S
    Am J Case Rep; 2016 Nov; 17():880-882. PubMed ID: 27893699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.